FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310159488> ?p ?o ?g. }

• W4310159488 endingPage "4304" @default.
• W4310159488 startingPage "4303" @default.
• W4310159488 abstract "Introduction Multiple Myeloma (MM) develops from well-defined precursors Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), where patients may remain stable or unknowingly rapidly progress to MM. Bone marrow (BM) biopsies are not routine for precursor disease management, and precursor patients are limited to monitoring a few biomarkers within peripheral blood (PB) for signs of progressive disease. Deep proteome profiling of PB plasma may help sensitively track disease, however, the complexity and dynamic range of plasma proteins has caused substantial limits of detection for MS-based proteomics. Technological advancements in multiplex assays with low cross-reactivity and minimal off-target events have enabled the use of plasma profiling for early disease detection, disease stage classification, defining high-risk disease features, and novel therapeutic target discovery. Here, we perform the first comprehensive plasma proteomic profiling study on patients across the MM disease continuum and longitudinal sequential samples from MM progressors and non-progressors. Methods We performed high-throughput plasma proteomic profiling for approximately 3000 proteins simultaneously using the Olink® Explore 3072 library and Proximity Extension Assay (PEA) technology. Briefly, targeted proteins are recognized with multiplex matched pairs of antibodies labelled with unique DNA oligonucleotides. Upon antibody binding, the oligonucleotides come into proximity, hybridize, and are extended to generate a unique sequence for protein identification using next generation sequencing (NGS) readout. We profiled a cohort of 174 individuals, including patients with MGUS (n=18), SMM (n=66), MM (n=18), and healthy individuals (n=72). Two time-point sequential samples were also profiled from MGUS to SMM progressors (n=17), SMM to MM progressors (n=17), MGUS non-progressors (n=9) and SMM non-progressors (n=27) with matched clinical follow-up time. Multi-timepoint samples from progressors range 0.48-5.88 years between samples (median of 1.53 years), and patients had a median clinical follow-up of 7.05 years. T-tests, ANOVAs, and a linear mixed effect (LME) model were used to identify proteins that change across disease stages, progression status, time, or their interaction. Results were adjusted for multiple testing using the Benjamini-Hochberg Method. Results We identified 1302 significantly dysregulated proteins with the majority upregulated in progressive disease. We discovered many proteins that were significantly differentially expressed in MGUS, SMM, and NDMM vs. healthy donors (n=169, 713 and 621), in MGUS vs. SMM (n=467), MGUS vs. NDMM (n=243), and SMM vs. NDMM (n=304). We validated the use of PEA to capture plasma cell soluble proteins consistent with previous findings to serve as positive controls, including BCMA, which was significantly elevated in SMM and MM, baseline samples from progressors, and SMM-MM sequential samples while non-progressors remained stable. Additional MM-relevant proteins were also significantly expressed in our dataset, some of which are current therapeutic targets, including SLAMF7, SDC1, IL-6, CD69, CXCL5, and PECAM1. Notably, MGUS and SMM samples expressed proteins involved in proteotoxic stress and osteolysis, while MM samples expressed regulators of plasma cell differentiation, calcium modulation, cytokine secretion, T cell activation, and lymphocyte migration. A total of 990 proteins were significant in LME analysis; 12 proteins were significantly elevated in baseline samples of progressors vs. non-progressors, and 23 proteins significantly increased in expression over SMM-MM progression. Notably, two novel proteins that are vital for calcium homeostasis and integrin-mediated cell adhesion overlapped between these comparisons. These may act as new biomarkers for disease at high-risk of progression to MM. Conclusions We performed the most comprehensive plasma proteomics study to date on MM disease stages and identified candidate high-risk disease biomarkers in longitudinal samples with significant clinical follow-up. Results reported here are preliminary and additional studies are underway to validate candidates in a larger cohort of patients and determine how best to integrate proteins into risk stratification models." @default.
• W4310159488 created "2022-11-30" @default.
• W4310159488 creator A5004207431 @default.
• W4310159488 creator A5007290974 @default.
• W4310159488 creator A5007585094 @default.
• W4310159488 creator A5007871652 @default.
• W4310159488 creator A5010749565 @default.
• W4310159488 creator A5019827043 @default.
• W4310159488 creator A5020129805 @default.
• W4310159488 creator A5020163280 @default.
• W4310159488 creator A5021621729 @default.
• W4310159488 creator A5023152679 @default.
• W4310159488 creator A5023955059 @default.
• W4310159488 creator A5026162401 @default.
• W4310159488 creator A5027483711 @default.
• W4310159488 creator A5036255260 @default.
• W4310159488 creator A5038511686 @default.
• W4310159488 creator A5040131948 @default.
• W4310159488 creator A5044638106 @default.
• W4310159488 creator A5055000089 @default.
• W4310159488 creator A5059227267 @default.
• W4310159488 creator A5062866982 @default.
• W4310159488 creator A5065488391 @default.
• W4310159488 creator A5072626646 @default.
• W4310159488 creator A5072990871 @default.
• W4310159488 creator A5086789120 @default.
• W4310159488 creator A5088842802 @default.
• W4310159488 date "2022-11-15" @default.
• W4310159488 modified "2023-09-26" @default.
• W4310159488 title "High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients" @default.
• W4310159488 doi "https://doi.org/10.1182/blood-2022-170346" @default.
• W4310159488 hasPublicationYear "2022" @default.
• W4310159488 type Work @default.
• W4310159488 citedByCount "1" @default.
• W4310159488 countsByYear W43101594882023 @default.
• W4310159488 crossrefType "journal-article" @default.
• W4310159488 hasAuthorship W4310159488A5004207431 @default.
• W4310159488 hasAuthorship W4310159488A5007290974 @default.
• W4310159488 hasAuthorship W4310159488A5007585094 @default.
• W4310159488 hasAuthorship W4310159488A5007871652 @default.
• W4310159488 hasAuthorship W4310159488A5010749565 @default.
• W4310159488 hasAuthorship W4310159488A5019827043 @default.
• W4310159488 hasAuthorship W4310159488A5020129805 @default.
• W4310159488 hasAuthorship W4310159488A5020163280 @default.
• W4310159488 hasAuthorship W4310159488A5021621729 @default.
• W4310159488 hasAuthorship W4310159488A5023152679 @default.
• W4310159488 hasAuthorship W4310159488A5023955059 @default.
• W4310159488 hasAuthorship W4310159488A5026162401 @default.
• W4310159488 hasAuthorship W4310159488A5027483711 @default.
• W4310159488 hasAuthorship W4310159488A5036255260 @default.
• W4310159488 hasAuthorship W4310159488A5038511686 @default.
• W4310159488 hasAuthorship W4310159488A5040131948 @default.
• W4310159488 hasAuthorship W4310159488A5044638106 @default.
• W4310159488 hasAuthorship W4310159488A5055000089 @default.
• W4310159488 hasAuthorship W4310159488A5059227267 @default.
• W4310159488 hasAuthorship W4310159488A5062866982 @default.
• W4310159488 hasAuthorship W4310159488A5065488391 @default.
• W4310159488 hasAuthorship W4310159488A5072626646 @default.
• W4310159488 hasAuthorship W4310159488A5072990871 @default.
• W4310159488 hasAuthorship W4310159488A5086789120 @default.
• W4310159488 hasAuthorship W4310159488A5088842802 @default.
• W4310159488 hasBestOaLocation W43101594881 @default.
• W4310159488 hasConcept C111919701 @default.
• W4310159488 hasConcept C126322002 @default.
• W4310159488 hasConcept C143998085 @default.
• W4310159488 hasConcept C187191949 @default.
• W4310159488 hasConcept C2776364478 @default.
• W4310159488 hasConcept C41008148 @default.
• W4310159488 hasConcept C70721500 @default.
• W4310159488 hasConcept C71924100 @default.
• W4310159488 hasConcept C86803240 @default.
• W4310159488 hasConceptScore W4310159488C111919701 @default.
• W4310159488 hasConceptScore W4310159488C126322002 @default.
• W4310159488 hasConceptScore W4310159488C143998085 @default.
• W4310159488 hasConceptScore W4310159488C187191949 @default.
• W4310159488 hasConceptScore W4310159488C2776364478 @default.
• W4310159488 hasConceptScore W4310159488C41008148 @default.
• W4310159488 hasConceptScore W4310159488C70721500 @default.
• W4310159488 hasConceptScore W4310159488C71924100 @default.
• W4310159488 hasConceptScore W4310159488C86803240 @default.
• W4310159488 hasIssue "Supplement 1" @default.
• W4310159488 hasLocation W43101594881 @default.
• W4310159488 hasOpenAccess W4310159488 @default.
• W4310159488 hasPrimaryLocation W43101594881 @default.
• W4310159488 hasRelatedWork W2069949469 @default.
• W4310159488 hasRelatedWork W2162314707 @default.
• W4310159488 hasRelatedWork W2355902447 @default.
• W4310159488 hasRelatedWork W2360955809 @default.
• W4310159488 hasRelatedWork W2404733967 @default.
• W4310159488 hasRelatedWork W2435227317 @default.
• W4310159488 hasRelatedWork W3004485101 @default.
• W4310159488 hasRelatedWork W3170099453 @default.
• W4310159488 hasRelatedWork W4232652152 @default.
• W4310159488 hasRelatedWork W4298045420 @default.
• W4310159488 hasVolume "140" @default.
• W4310159488 isParatext "false" @default.
• W4310159488 isRetracted "false" @default.
• W4310159488 workType "article" @default.